Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)
about
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye diseaseImpact of the controlled release of a connexin 43 peptide on corneal wound closure in an STZ model of type I diabetesLifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.Recent advances in ophthalmic drug delivery.Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroidsPazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.Effect of dietary antioxidant supplementation (Cuminum cyminum) on bacterial susceptibility of diabetes-induced rats.Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to GlucoseLifitegrast: A novel drug for treatment of dry eye disease.Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Anti-inflammatory therapy for diabetic retinopathy.Inflammation in diabetic retinopathy.Inflammation and diabetic retinal microvascular complications.Diabetic macular edema: current and emerging therapies.Microparticles, not only markers but also a therapeutic target in the early stage of diabetic retinopathy and vascular aging.Lifitegrast for the treatment of dry eye disease in adults.Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye DiseaseLifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eyeOcular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.Dry eye syndrome: developments and lifitegrast in perspective.Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
P2860
Q26746232-A336CD02-1FD8-46CB-B98A-D8C0C17C8AFAQ28539090-34E84EF3-1EDF-400B-B14A-1774CF340286Q33739879-D0DFF9B2-ED4F-4964-AD29-C6098798D68FQ34636338-074BB25E-EE2D-42F6-99F5-9E4519C0B2B7Q34856993-5895B532-CBB1-4772-AEEC-4F64630CCC0EQ35600275-8C0ABA2F-DB3B-455E-B4C1-49091CBCCE1AQ36093262-E006E31A-512B-4BB9-80DD-8810D9604C7AQ37140593-F2B632E7-DBC3-4EAC-A497-9BD3BC2D4918Q37165322-FD26EE32-9FC6-4938-91F7-4B3EB1512E16Q37591609-C3FC83D5-42AA-4B91-9B96-E7818C2F6033Q37627442-2131DD98-731B-4480-84E3-ECF231827191Q37873482-91AA9DF3-D6C6-4323-91B0-16D788FCAC37Q37884176-6771A5D5-1FB4-43FF-95C6-2816E273791FQ37911285-25745A9C-73ED-451B-9C50-BA92777C1FAFQ37985854-0764FEE4-0C0D-486F-8B88-34F94CBD946FQ38012180-8CF1CA85-00AB-4BA4-9F5F-583DD4D8CE89Q38608475-8143445B-1FAF-41B4-9702-4C91D72738EBQ38895113-B9422A31-00F2-4872-9D4C-4392A7D60404Q39025675-60B0C77A-D412-48E2-A8E9-404750101C60Q39069560-74445702-572F-4EA1-8DDD-B6B7EE9DC6B3Q39410312-366F26F3-3D9E-441D-915E-5DC5A3CB4894Q39730888-666EACC7-B007-4C6B-A189-5176BE7159B2Q40356553-35AFDB8E-63A0-4722-A000-1DF26849747EQ42060377-8188A3AC-4D6A-40E8-B601-E00FB4CD321DQ47268214-3226EBA2-0B1D-4152-8CBD-E8381E83C26EQ47639135-62FD090F-42E9-48E4-BED6-16CD7AE379A9Q51742251-E902F1CA-1CC6-428D-9918-AB45437BD2D4
P2860
Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Delivery of SAR 1118 to the re ...... l of diabetic retinopathy (DR)
@ast
Delivery of SAR 1118 to the re ...... l of diabetic retinopathy (DR)
@en
Delivery of SAR 1118 to the re ...... veness in a rat streptozotocin
@nl
type
label
Delivery of SAR 1118 to the re ...... l of diabetic retinopathy (DR)
@ast
Delivery of SAR 1118 to the re ...... l of diabetic retinopathy (DR)
@en
Delivery of SAR 1118 to the re ...... veness in a rat streptozotocin
@nl
prefLabel
Delivery of SAR 1118 to the re ...... l of diabetic retinopathy (DR)
@ast
Delivery of SAR 1118 to the re ...... l of diabetic retinopathy (DR)
@en
Delivery of SAR 1118 to the re ...... veness in a rat streptozotocin
@nl
P2093
P2860
P356
P1476
Delivery of SAR 1118 to the re ...... l of diabetic retinopathy (DR)
@en
P2093
Charles A O'Neill
Craig Struble
Elizabeth Prescott
Namdev B Shelke
Peter Thomas
Ruchit Trivedi
Uday B Kompella
Vidhya R Rao
P2860
P304
P356
10.1167/IOVS.09-5144
P407
P577
2010-05-05T00:00:00Z